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We were hoping
to have the
survey results available for this issue of
the newsletter. Unfortunately, the final
summary findings have not been
completed. Preliminarily, I can report
that the overall. response rate was
approximately 20% with most
characterizing their relationships
favorably. A good working
relationship was characterized as
physicians and hospital working in a
cooperative way to achieve mutual
goals with honest and open two-way
communication and mutual trust and
respect. The themes of open
communication and reward and
recognition of physicians' efforts and
contributions were at least part of the
answers to many of the questions in the
survey. We hope by the next
newsletter to have a more formal
report for you.
I wish to express my sincere thanks to
all of you for the opportunity to serve
in this position. With the high caliber
physicians on our medical staff being
given opportunities to maximize their
potential, I believe we will continue to
grow and function as professionals in
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the highest sense of that term. John
Castaldo represents us well in this
sense of professionalism as we
continue to strive to offer the best
possible healthcare for our community.
Happy Holidays to All. Best Wishes
for the New Year.

Jo~dio,

M.D.
President, Medical Staff

Happy
Holidays!

Plastic and Reconstructive Surgeon to Serve as
President-Elect
Robert X. Murphy, Jr., M.D.,
plastic and reconstructive surgeon, was
recently nominated and elected to serve
as Medical Staff President-elect for a
two-year term beginning January 1,
1995.
Dr. Murphy joined the Medical Staff in
1989, and is a member of the
Department of Surgery, Division of
Plastic and Reconstructive
Surgery/Trauma, Section of Bums.
A graduate of New York University,
New York, N.Y., Dr. Murphy
completed a general surgery internship
followed by a two-year general surgery
junior residency at Beth Israel
Hospital, Boston, Mass. He then
completed one year of general surgery
training at Morristown Memorial

Hospital, Morristown, N.J. Dr.
Murphy then completed a two-year
plastic and reconstructive surgery
residency at Montefiore Medical
Center and Albert Einstein College of
Medicine, Bronx, N.Y., followed by a
clinical fellowship in hand surgery at
Bellevue Hospital and New York
University Medical Center, New York,
N.Y.
Dr. Murphy is certified by the
American Board of Plastic Surgery
with certification of Added
Qualification in Surgery of the Hand.
Dr. Murphy is a member of Plastic
Surgeons Professional Group, Inc.,
located at 1230 S. Cedar Crest
Boulevard, Allentown.

At-Large Member Needed for Medical Executive
Committee
As a result of the election of Robert X.
Murphy, M.D., as President-elect of
the Medical Staff, an at-large seat has
become vacant on the Medical
Executive Committee.
Nominations to fill this seat (with a
term from March, 1995 through June
30, 1996) should be submitted in
writing to John E. Castaldo, M.D.,
Chairman of the Nominating
Committee, via the Medical Staff
Services Office, Cedar Crest & I-78,
or verbally to Joseph A. Candio,
M.D., Medical Staff President; or

John W. Hart, Vice President. All
nominations must be submitted prior to
March 1, 1995.

If you have any questions regarding
this is::ue, please contact Dr. Castaldo
or Mr. Hart at 402-8900.
.·

Mark your calendar!

.The next
Physician Recognition Dinner will be
held.onSaturday,April1, 1995, at
the Holiday Inn Conference Center in
Fogelsville. More info to come.

Page 2

New Am~ulatory Surgery Unit to Open at

17th & Chew
Following over a year of planning and
construction, the hospital's new
Ambulatory Surgery Unit is scheduled
to open on January 9, 1995 at 17th &
Chew.
The Lehigh Valley Hospital
Ambulatory Surgery Unit, which will
be located on the second floor, is
dedicated to providing cost-efficient,
patient focused care, and will include
the following areas:
• A decentralized registration area to
expedite patient registration.
• A unit specific centralized
documentation processing area to
assure chart document preparation and
processing.
)

• Pre-admission testing, which is
currentlylocated in Suite ill of 401
N. 17th Street, will move adjacent to
the unit. This will offer expanded
appointment scheduling which will be
completed at the time of OR
scheduling. Pre-admission processing
visits will be scheduled for all
ambulatory surgery patients to provide
the time for an anesthesia visit and
avoid delay on the day of procedure.
For the convenience of your patients,
unscheduled visits to pre-admission
processing will be accommodated by
contacting the scheduling department.

ambulatory surgery will continue to be
staged pre- and post-procedure in the
pediatric unit on the 5th floor.)
• Operating room suite consisting of
eight operating rooms and a
urodynamics suite. ·
• Two minor procedure rooms.
• A 13-bay Post Anesthesia Care
Area.
Packets including information about the
new Ambulatory Surgery Unit will be
distributed to physicians' offices prior
to the opening of the new unit.
PLEASE NOTE: Outpatient G.I. lab
procedures, myelograms, arteriograms,
and lithotripsy procedures will continue
to be performed at Cedar Crest & I-78.
These cases will be scheduled through
centralized scheduling, and the patient
will be staged pre- and post-procedure
through 4B and 5B, respectively.
If you have any questions regarding the
new Ambulatory Surgery Unit, please
contact Barbara Frantz, Director,
Ambulatory Surgery Unit Staging/
PAP/PACU, at 402-8599 or Virginia
Kovalovich, Director, Ambulatory
Surgery Unit OR, at beeper 1052.

• Staging and recovery areas (24) for
pre- and post-:-procedure care of
patients.
• Pediatric staging and recovery areas.
(Pediatric outpatients scheduled for
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Senior Vice President of Clinical Services Announced
Robert J. Laskowski, M.D., formerly
of Farmington, Conn., has been named
Senior Vice President of Clinical
Services, a new position at Lehigh
Valley Hospital, effective January
1995. In his position, Dr. Laskowski
will coordinate the activities of the
hospital's clinical departments, assure
the delivery of medical services follows
established procedures, and oversee
medical education and quality
assurance programs.
Dr. Laskowski was previously group
medical director and president,
Northeast Permanente Medical Group,
Farmington, and a member of the
medical faculty at the University of
Connecticut. He had also served as the
group's associate regional medical
director and vice president.
Dr. Laskowski earned his bachelor's
degree, summa cum laude, medical
degree, and M.B.A. from the

University of Pennsylvania. He
completed an Internal Medicine
residency at the University of Chicago
Hospitals and Clinics, and a fellowship
in General Internal Medicine at the
Hospital of the University of
Pennsylvania. He was a Robert Wood
Johnson Foundation ·Clinical Scholar at
the University of Pennsylvania, 1981 to .
1983.
Dr. Laskowski is certified in Internal
Medicine with added qualifications in
Geriatric Medicine by the American
Board of Internal Medicine. He is a
member of the American College of
Physicians, the American Medical
Association, the Society for General
Internal Medicine, the American
Geriatrics Society, the Gerontological
Society of America, the American
College of Physician Executives, and
the American Public Health
Association.

Administrator for Skilled Nursing Facility Named
Terry C. Tressler, of Sewell, N.J., has
been named administrator for Lehigh
Valley Hospital's skilled nursing unit at
17th & Chew. In this newly created
position, he will be responsible for
managing all of the activities of the
new 52-bed sub-acute care facility.
The unit will give short-term care to
patients who are medically stable but
not well enough to be discharged or
transferred to another facility. The
hospital received approval for the
project this past summer and plans to
begin operations in February, 1995.

Since 1979, Mr. Tressler has served in
administrative positions at nursing and
retirement centers in Philadelphia and
southern New Jersey. Most recently,
he was administrator of Bala Nursing
and Retirement Center, a 180-bed
facility in Philadelphia.
Mr. Tressler earned a law degree from
Temple University School of Law. He
received a master's in public
administration and a bachelor's in
health planning and administration
from Pennsylvania State University.
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Vice President of Public Affairs Named
Mary Alice Czerwonka, former
director of Corporate Communications
for the Fairview Health System,
Minneapolis, Minn., was recently
named Vice President of Public Affairs
at Lehigh Valley Hospital.
In this position, Mrs. Czerwonka will
be responsible for planning and
overseeing the implementation the
hospital's internal and external public
relations strategies.
Prior to her position with the Fairview
Health System, Mrs. Czerwonka held
public relations management posts at

the Ramsey Clinic/St. Paul Ramsey
Medical Center, St. Paul. She also
served as a reporter and editor for The
Times, Hammond, Ind.
Mrs. Czerwonka earned a bachelor's
degree in journalism from Indiana
University, Bloomi.Iigton, Ind. She
was a board member of the American
Society for Health Care Marketing and
Public Relations and is an Accredited
Business Communicator and member
of the Accreditation Board of the
International Association of Business
Communicators.

ABC News' 20/20 Films Stroke Surgery Story at
Lehigh Valley Hospital
National network television recently
turned its spotlight on Lehigh Valley
Hospital. ABC News' 20/20
Magazine program chose the hospital
as the focus of a story about the results
of a national research study. The trial
found that surgery is the best medicine
for preventing strokes in persons who
have blocked carotid arteries but no
related symptoms.

image or sound bite to take back to the
editing room in Boston where the
segment will be assembled.

During five days of filming at the
hospital, nearly 15 hours of interviews,
surgeries, patient exams, and
diagnostic tests were captured on video
tape. Often starting before sunrise and
lasting until after dark, a cameraman,
sound technician, and two producers
from 20/20's medical branch pursued
doctors, patients, nurses, and other
professionals in search of yet another

Lehigh Valley Hospital was chosen as
the site for filming because of its
strong track record in recruiting
patients for the Asymptomatic Carotid
Atherosclerosis Study (ACAS). This
study compared surgery with medicine
in treating persons with major carotid
artery blockage.

According to producer, Roger Sergei,
the story will be aired in early January
in 20/20's regular Friday night slot, 10
to 11 p.m. About 85 percent of the 10
to 12 minute piece will feature scenes
shot at Lehigh Valley Hospital.

Continued on Page 6
Page 5

Continued from Page 5

Lehigh Valley Hospital recruited more
patients-- 142 --than any of the other
39 participating hospitals, and the
efforts of the hospital's principal
investigator, John E. Castaldo, M.D.,
stood above those of the rest
throughout the United States and
Canada.

Highlighting the filming was an hourlong· interview between Dr. Timothy
Johnson, 20/20's easy-to-spot medical
editor/host, and Dr. Castaldo.

Medical Staff/Administrative Exchange Sessions
On November 10, the first Medical
Staff/ Administrative Exchange Session
was held in an attempt to encourage
the mutual exchange of information
between members of the Medical Staff
and senior management in an informal,
relaxed atmosphere.

Due to the apparent success of the first
session, beginning in January, Medical
Staff/Administrative Exchange Sessions
will be held on a regular basis. Listed
below are the dates for the Exchange
Sessions for 1995:

January 19, February 16, March 16,
April 20, May 18, June 15, July 20,
August 17, September 21, October
19, November 16, and December 21.

All sessions will be held in Conference
Room 1, Side B of the John and
Dorothy Morgan Cancer Center, from
5:30 to 7:30 p.m. As space is limited
to 40 people, registration will be taken
on a first-come, first-serve basis.
Part of each session will be dedicated
to answering questions. In order to
have an opportunity to thoroughly
research questions, we ask that they be
submitted in advance.
For more information or to register for
any of the above sessions, please
contact Janet M. Seifert in Physician
Relations at 402-9853.

TV Remote .Control Units Installed at Cedar Crest
New televisions with remote control
units have been installed in patient
rooms at Cedar Crest & I-78. The
remote is cable mounted to the wall at
the head end of the patient's bed.

melted remotes being placed on the
overbed light fixture. As a safety
reminder, please remember that these
light fixtures get extremely hot and that
nothing is to be placed on them.

On several occasions, hazardous
conditions have occurred as a result of

Your attention to this matter is
appreciated.
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Cancer Staging Forms
During the last year, the Cancer
Committee has worked with the
Medical Records Department to
develop a process that will ensure the
accrual staging of cancer. Staging
forms along with the proper usage of
these forms was developed and
approved by the Cancer Committee,
Medical Records Committee, and
Medical Executive Committee.
The process will be implemented on
January 9, 1995, and will be managed
in the following way:
• Pathology will attach the site
specific staging form to the positive
pathology report.
• A pathologist will check/ complete
and sign the histopathologic
classification form.
• The attending physician will
check/complete and sign the clinical
classification and staging form.

• Medical Records Department, during
post discharge chart analysis, will
verify the presence of a staging form
on charts containing a cancer diagnosis
and/or positive pathology report.
• Missing forms will be placed on the
chart by a Tumor Registrar.
• Charts with missing staging forms
will be flagged as deficient and
managed by the Medical Records
Department as other deficiencies.
By managing the staging of cancer in
this manner, Lehigh Valley Hospital
will be able to compare its experience
to that of other facilities, be prepared
for a soon-to-be implemented JCAHO
requirement, and most importantly,
enhance the care and treatment of the
patient with cancer.
If you have any questions about this
issue, please contact Sue Cassium in

the Medical Records Department at
402-4451, or Andrea Geshan, Tumor
Registry, and 402-0526.

Neutropenic Patient Accommodations
Patient care accommodations for the
neutropenic/immunosuppressed patient
were recently evaluated by David
Prager, M.D., chief, Division of
Hematology/Medical Oncology, Luther
V. Rhodes ill, M.D., chief, Division
of Infectious Diseases, and Irene
Ehrgott, Oncology Clinical Nurse
Specialist. In the past, the practice at
Lehigh Valley Hospital was to place
the immunosuppressed and/or
neutropenic patient in a semi-private
room without a roommate. Concern

for appropriate bed utilization
prompted a survey of 10 of the 50
leading cancer centers to determine
alternate standards of care for the
immunosuppressed patient.
As a result of the benchmarking
survey, literature review and physician
input, the following. changes to our
patient accommodations were initiated
as of October 21, 1994:
Continued on Page 8
Page 7
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The immunosuppressed and/or
neutropenic patient may be placed in a
semi-private room with a roommate.
Recommendations for the care of the
immunosuppressed/neutropenic patient
are as follows:
• Roommates of neutropenic patients
will be screened daily by the nursing
staff for:
o Open draining wounds not

covered by dressing due to
wound size or location.

o Contagious infectious
diseases such as disseminated
varicella zoster, herpes simplex,
tuberculosis, measles, mumps,
influenza, infectious diarrhea
(only if patient has poor
hygiene or is confused),
pneumonia (only if due to TB
or staph aureus).

• Increase or decrease of infection rate
for the immunosuppressed and/or
neutropenic patient.
• Compliance of handwashing for staff
and visitors.
• Compliance with requirements of
screening for roommates and visitors.
• Bed utilization.

• Fiscal aspects.
Visitors will also be provided with
guidelines regarding precautions for
patients with low white blood cell
counts.
If you have questions or need .
additional information, please contact
Dr. Rhodes at 402-8438, or Mrs.
Ehrgott at beeper 1500.

o Live viral vaccines for
measles, mumps, rubella or oral
polio vaccine given within two
months.
• Both staff and visitors must wash

their hands using disinfectant soap
upon entering and leaving the patient's
room.
• Visitors will be screened the same as
patient's roommates.
• Visiting guidelines will be
emphasized and discussed with ALL
PATIENTS, including family. Limit
2-3 visitors at a time.
The following outcomes will be
monitored for one year:

;:;~-~~~11~1~~~~····!
.

·.. '

··.·

·.··. ·.

:.-.·· . . . . .

·

.

Page 8

Laboratory- Update
The Microbiology/Virology
Department has begun its Respiratory
Virus Surveillance program for the
1994-1995 flu season. The value of
the surveillance program is to alert the
medical staff and other physicians
which viruses are circulating within the
community in order to ensure
appropriate immunization of their
patients and to activate preventive
measure to protect those for whom
respiratory viral infections may be life
threatening.
Last year's predominate isolate was ABeijing. This year's vaccine contains
B-Panama, A-Texas, and AShangdong. No isolates have been
recovered in Pennsylvania to date.
Mic~biology/Virology

)

will supply
spectmen collection kits consisting of a
sterile container with phosphate buffer
saline to gargle, a tube of viral
tran~rt media, case history form, and
a climcallaboratory requisition form.
To collect the specimen:

• The specimen should be collected
within two days and no later than three
days from the onset of respiratory or
flu-like symptoms.
• Gargle with sterile saline into
container.
• Spit saline back into container.

• Complete Virology History form
which is included in plastic pouch.
• Complete the Clinical Laboratory
Requisition Form for each patient's
specimen for outside accounts.
Specimens from patients seen in the
Emergency Departments will be
ordered through Phamis with the test
code "!NFL" for an-Influenza A/B
screen or "RVCU" for a complete
Respiratory Virus study. (Outside
accounts, please specify if just an
influenza screen is wanted.) The cost
of an Influenza Screen is $50, and the
cost for a full respiratory virus workup
is $85.
• Specimens from the Emergency
Departments should be hand delivered
to Microbiology on wet ice.
Specimens from outside accounts
should be refrigerated until courier
pick-up and should be transported on
wet ice.
Once the specimen is received in the
laboratory, it will be tested for
Influenza A and B (and other viruses
requested). Positive results will be
phoned. Final reports will be issued as
soon as the isolate is identified or when
the specimen is determined to be
negative. (Five days for Influenza
Screen, two weeks for complete
respiratory virus culture.)
For more information or to obtain
collection kits, please contact
Microbiology at 402-8190.

~

Pour saline throat washing directly
mto the tube of pink fluid.

J

• Label tube with patient's name, date,
and location, and place on wet ice.
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• WluJt's New at 17th & Chew

..
Gompel. Pathology in Gynecology
and Obstetrics. 4th ed. Lippincott,
1994.

Library
News

Piper. Motor Assessment of the
Developing Infant. Saunders, 1994.
Aquilera. Crisis Intervention. 7th ed.
Mosby, 1993.

Fogelman. An Atlas of Clinical
Nuclear Medicine. 2d ed. Mosby,
1993.
Socioeconomic Characteristics of
Medical Practice. AMA, 1994 (19821993 data)
Froelicher. Manual of Exercise
Testing. 2d ed. Mosby, 1994.

• library Trivill
Okeson. Management of
Temporomandibular Disorders and
Occlusion. 3rd ed. Mosby, 1993.
Donnez. Atlas of Laser Operative
Laparoscopy and Hysteroscopy.
Parthenon, 1994.

• WluJt's New at Cedar Crest & 1-78

Most/lease expensive books purchased
during 1994:
Haubrich. Bockus-Gastroenterology.
5th ed. Saunders, 1995. 4 vol. set$635.00.
Conover. Pocketguide to Electrocardiography. 3rd ed. Mosby, 1994.
$19.95.

The Official ABMS Directory of
Board Certified Medical Specialists.
27th ed. Marquis Who's Who, 1995.

News from Research
A call for abstracts has been issued by
the following organizations:
The American College of Surgeons
80th Annual. Clinical Congress to be
held in New Orleans, La., on October
22, 1995. Submission due date is
March 31.
The American Diabetes Association
55th Annual Meeting Scientific
Sessions to be held in Atlanta, Ga., on
June 10, 1995. Submission due date is
January 6.
The American Psychiatric Association
Annual Meeting to be held in Miami
Beach, Fla., on May 20, 1995.
Submission due date is January 15.

The American Society of Plastic and
Reconstructive Surgery Annual
Meeting to be held in Montreal,
Canada, on October 7, 1995.
Submission due date is February 22.
The Society for Pediatric Research
Annual Meeting to be held in San
Diego, Calif. on May 8, 1995.
Submission due date is January 4.
The Society of Nuclear Medicine
Annual Meeting to be held in
Minneapolis, Minn., on June 12, 1995.
Submission due date is January 4.
For instructions, forms, and further
information, please contact Kathleen

Moser in the Research Department at
402-8747.
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Congratulations!
Broce R. Ganey, D.P.M., podiatrist,
was recently notified by the American
Board of Podiatric Orthopedics and
Primary Podiatric Medicine that he
successfully completed the certification
examination and is now a Diplomate of
the Board in that section.

Papers, Publications and Presentations
Members of the hospital's staff
recently presented a poster,
Microalbuminuria: A Positive
Predictive Value for Coronary Heart
Disease?, at the American Society of
Nephrologists National Meeting held in
Orlando, Fla. Those involved in the
poster presentation included: David
del Rosario, M.D., medical resident;
Mary Ann Gergits, R.N., research
nurse; Nelson P. Kopyt, D.O.,
nephrologist; Carolyn Peters, R.N.,
3C; and James F. Reed, Ph.D.,
Director of Research.

James W. Jaffe, M.D., chief, Section
of Cardiovascular/Interventional
Radiology, will present two papers at
the Annual Meeting of the Society of
Cardiovascular and lnterventional
Radiology to be held on March 27,
1995 in Ft. Lauderdale, Fla. The
papers are titled Treatment of
Symptomatic Lower Extremity Deep
Venous Thrombosis with Retrograde
Catheter Placement and Urokinase
Infusion and Assessment of Venous.
Valvular Damage after Retrograde
Venous Passage of a CatheterGuidewire Infusion System.

Peter A. Keblish, M.D., chief,
Division of Orthopedic Surgery, was a
member of the faculty in a recent
symposium, Revision Hip and Knee
Surgery: The Cost Equation, held in
Scottsdale, Ariz. Dr. Keblish
presented papers on three topics,
namely, Surgical Approaches for the
Stiff Knee in Revision Total Knee
Arthroplasty, Bone Graft Options,
and Treatment of the Infected Total
Knee Arthroplasty. He also served
on the discussion panels and directed a
workshop on Revision Total Knee
Replacement. The symposium was
directed at both the academic and
economic ramifications of the costly
subject of Total Joint Revisions.
Stephen K. Klasko, M.D., vice chair
and residency program director,
Department of Obstetrics and
Gynecology, was recently informed
that his abstract, Psychologic Effects
of Hysterectomy - Development of a
Biopsychosocial Model, has been
accepted for poster presentation at the
23rd Annual Meeting of the American
Society for Psychosomatic Obstetrics
and Gynecology to be held February
23-25, 1995 in Virginia.
Continued on Page 12
Page 11
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Yasin Khan, M.D., anesthesiologist,
presented four poster abstracts at the
American Pain Society Annual Meeting
held recently in Miami, Fla.
The poster abstracts included: Trial

Percutaneous Peripheral Nerve
Stimulation (PNS): A Technique to
Determine Efficacy Prior to Implant;
Is Percutaneous Spinal Cord
Stimulation Cost Effective for the
Treatment of Pain Dysfunctional
Syndrome Compared to Epidural
Infusions?; Spinal Cord Stimulation
for Atypical Facial Pain and
Trigeminal Neuralgia; and Use of
Spinal Cord Stimulator for Chronic
Pancreatitis.

Steven J. Lawrence, M.D.,
orthopedic surgeon, recently authored
an article, The Sural Nerve in the

Foot and Ankle: An Anatomic Study
with Clinical Surgical Implications.
The article was published in the
September, 1994 edition of Foot &
Ankle lntei7Uitional.
Thomas D. Meade, M.D., orthopedic
surgeon, moderated the Healthy Heart
program at Muhlenberg College on
November 14.

Upcoming Seminars, Conferences and Meetings
Regional Symposium
Series VI
Endocrinology Update will be held on
Saturday, January 14, 1995, from 7:30
a.m. to 12:30 p.m., in the Auditorium
of Lehigh Valley Hospital, Cedar Crest
& I-78.
Physicians, nurses, and other health
professionals interested in an update in
endocrinology will benefit from this
program.
At the completion of this program, the
participant should be able to:
• clinically differentiate and institute
initial workup for androgen problems
• select an appropriate treatment

program for a specified type of

• explain. the presence of several
thyroiditis conditions and describe their
long term clinical course
• discuss the current theory of insulin
resistance and how it relates to disease
states and treatment
• describe those patients with
hypertension who may have a
remediable endocrine cause.

Sixth Annual Symposium in
Geriatrics will be held on Saturday,
January 28, from 8 a.m. to 3 p.m., in
the Auditorium of Lehigh Valley
Hospital, Cedar Crest & I-78.
Physicians, nurses, medical residents,
pharmacists, social workers, and other
health professionals interested in an
update in geriatrics will benefit· from
the program.

osteoporosis
Continued on Page 13
Page 12
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At the completion of this program,
participants should be able to:
• identify current approaches to the
care of the elderly including treatment
for osteoporosis and benefits of
geriatric research
• identify the impact of
pharmacokinetic and pharmacodynamic
changes in the elderly on drug therapy
compliance and apply strategies to
prevent or minimize adverse treatment
outcomes
• identify and incorporate a variety of
community resources and placement
options for elderly patients and their
caregivers
• describe the changes in the eye
which occur with aging and
differentiate normal changes from
disease process
.
• identify common causes of urinary
incontinence, describe factors affecting
continence, and identify three
approaches to the management of
urinary incontinence in the elderly.

Psychiatry Grand
Rounds
Rochester Capitation Program for
the Mentally m will be presented by
Sylvia K. Reed, Ph.D., Project
Director, Management Information
Systems, Department of Psychiatry,
University of Rochester Medical
Center, and Ethel Davis Jackson,
Associate Commissioner for Adult
Services, New York State Office of
Mental Health, on Thursday, January
19, from noon to 1 p.m., in the
Auditorium at 17th & Chew.
As lunch will be provided, preregistration is requested. For more
information or to register, contact Lisa
Frick in the Department of Psychiatry
at 402-2810.

For more information on the above
programs, please contact Human
Resource Development at 402-1210.

Primary Care Seminar
Otitis Media will be presented by
Charles F. Smith, M.D., on
Wednesday, December 21, from 10
a.m. to noon, in the Auditorium at
17th & Chew.
For more information, contact Karen
Nodoline in the Department of Family
Practice at 402-4950.
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• Wanted -- M~(:lical Director,
Skilled Nursing Facility, Lehigh
Valley Hospital, 17th & Chew-Primary care physician sought as
Medical Director for Lehigh Valley
Hospital's hospital-based, interim
care skilled nursing facility. Will
oversee operations of new 52-bed
unit and participate in medical
management of patients. Board
certification required. Experience
working in skilled nursing facility
preferred. Position is part-time (.25
FTEl. Interested candidates please
send CV, in confidence, to Francis
Salerno, M.D., Chair, Search
Committee, c/o Carol Voorhees,
Physician Recruitment Department,
1243 S. Cedar Crest Boulevard,
Allentown, PA 18103, 402-3090,
fax- 402-9858.
• For Sale or Lease -- Springhouse
Professional Center, 1575 Pond
Road. Ideal for physician's office.
Approximately 2,500 sq. ft.
• For Sale -- Office building at
Northeast corner of 19th and Turner
Streets in Allentown. Upper level 2,400 + sq. ft., large waiting room,
two large consultation rooms, five
exam rooms, etc. Lower level2,300 + sq. ft. Parking lot for 16
cars.
• For Sale -- Medical office suite in
the 1230 S. Cedar Crest Boulevard
Medical Office Building. 1,225 sq.
ft.
• For Lease -- Office to sublet on
Monday, Tuesday, Thursday, and
Friday. 950 sq. ft. Common
waiting area. Lakeside Professional
Building, Quakertown.

• For Lease -- Slots are currently
available for the Brown Bag suite at
Kutztown Professional Center. Ideal
for satellite location.
• For Lease -- Several time slots are
available in the medical office
building on the campus of Gnaden
Huetten Memorial Hospital in
Lehighton.
• For Lease -- Medical-professional
office space located on Route 222
in Wescosville. Two 1,000 sq. ft.
offices available or combine to form
larger suite.
• For Lease -- Medical office space
located in Peachtree Office Plaza in
Whitehall. One suite with 1 ,500 sq.
ft. (unfinished - allowance available),
and one 1,000 sq. ft. finished suite.
• For Lease -- Specialty practice
time-share space available in a
comprehensive health care facility.
Riverside Professional Center, 401 9
Wynnewood Drive, Laurys Station.
Half- or full-day slots immediately
available.
• For Lease -- Professional office
space available in an established
psychology and psychotherapy
practice at 45 N. 13th Street,
Allentown. Large, warm Victorian
building in a relaxed atmosphere.
Secretary and billing available and
included in some leases. Furnished
or unfurnished full offices and
sublets available. Utilities included.
For more information or for
assistance in finding appropriate
office space to meet your needs,
contact Janet M. Seifert, Physician
Relations Rep, at 402-9853.
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WHO'S NEW
The Who's New section of Medical
Stoff Progress Notes contains an
update of new appointments, address
changes, newly approved privileges,
etc. Please remember that each
department or unit is responsible for
updating its directory, rolodexes, and
approved privilege rosters.

Medical Staff
Appointments

D. Lynn Morris, MD
Department of Medicine
Division of Cardiology
Coronary Rotoblator Privileges
Active

Change of Status
James R. Clifford, ·MD
Department of Family Practice
From Courtesy to Emeritus Courtesy
LeRoy B. Gerchman, MD
Department of Family Practice
From Courtesy to Referring

Robert H. Schmidt, DO
(solo)

1227 Liberty Street
Suite 303
Allentown, PA 18102-2606
(610) 437-1959
Department of Family Practice
Provisional Referring

Christopher J. Stille, MD
(Children's Healtb.Care- Dr. Toft)

Children's HealthCare
Children's HealthCare Center·
1517 Pond Road
Allentown, PA 18104-2250
(610) 395-4444
Department of Pediatrics
Division of General Pediatrics
Provisional Active

Additional Privileges
Victor J. Celani, MD
Department of Surgery
Division of Vascular Surgery
Active
Placement of Transluminal Peripheral
Arterial Stents

Michael J. Kareha, DMD
Department of Dentistry
Division of Periodontics
From Consulting to Referring

Laura Kramer, DO
Department of Medicine
Division of General Internal Medicine
From Consulting to Referring

John J. Mecca, MD
Division of Family Practice
From Courtesy to Referring

Lisa H. Medina, MD
Department of Family Practice
From Courtesy to Provisional Active

Howard S. Selden, DDS
Department of Dentistry
Division of Endodontics
From Courtesy to Emeritus Referring

Kenneth D. Truscott, MD
Department of Family Practice
From Courtesy to Referring
Continued on Page 16

)
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Continued from Page 15

Practice Disassociation
John A. KibeJstis, MD no longer
associated with Pulmonary Associates,
PC
M. Bruce Viechnicki, MD no longer
associated with College Heights
OBGYN Associates, PC

Address and Telephone
Number Changes
John A. Kibelstis, MD
1251 S. Cedar Crest Blvd.
Suite 107A
Allentown, PA 18103
(610) 435-6502

Death
George E. Moerkirk, MD
Department of Emergency Medicine
.Division of Pre-hospital Emergency
Medical Services
Emeritus Active

Allied Health
Professionals
Appointment
Deborah R. Miller, PNP
Physician Extender
Professional - RN
(ABC Pediatrics - Dr. Levick)

Address Change
Edward A. Schwartz, DPM
Coordinated Health Systems
2775 Schoenersville Road
Bethlehem, PA 18017
(610) 861-8080, Ext. 250
FAX: (610) 861-0258

Elizabeth M. DelPezzo, PbD
Park Professional Building
2200 W. Hamilton Street
Suite 307
Allentown, PA 18104-6382

M. Bruce Viecbnicki, MD
M. Bruce Viechnicki, MD &
Associates PC
3131 College Heights Blvd.
Allentown, PA 18104
(610) 366-7000

Resignations
lain F. Black, MD
Department of Pediatrics
Division of Cardiology
Consulting

Norman C. Kramer, MD
Department of Medicine
Division of General Internal Medicine
Emeritus Consulting
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Autoimmune Thyroid Disease: Highly Sensitive
Assays for Thyroid Auto-Antibodies
Thyroglobulin (Tg) is a very large
molecule produced by the thyroid cells
and stored in the thyroid colloid.
Thyroid hormones are synthesized on
Tg which therefore forms the nidus on
which the synthesis of T4 and T3 takes
place. The enzyme which allows for
the formation of T4 and T3 is thyroid
peroxidase (TPO). This has recently
been verified on the microsomal
antigen in chronic thyroiditis.

thyroid antibodies are detectable years
before serum TSH levels become
elevated, the screening with TPO and
TgAb may identify a subgroup whose
TSH levels may require monitoring on
a yearly basis. Epidemiologic data
suggests that patients with an increased
TSH level and normal T4 will progress
to overt thyroid failure at a rate of 5 %
per year if they also have increased
titer of anti-TPO autoantibodies.

The measurement of thyroid peroxidase
(TPO) auto-antibodies used with the
thyroglobulin antibody (TgAb) test can
be of considerable value in the
diagnosis of thyroid diseases such as
Autoimmune Chronic Thyroiditis
(Hashimoto's Disease). Complement
fixing immunoglobulin G polyclonal
autoantibodies directed against a
thyroid specific cell surface antigen
TPO are capable of destroying
follicular cells. The prevalence of
TPO antibodies among adults,
especially women, is approximately
10% . Some studies of pregnant
women have reported an incidence of
positivity as high as 20%. Because of
this high prevalence for thyroid
'antibodies, this test has been promoted
as a primary screening test for
autoimmune hypothyroidism. Since

A particular group that would
especially benefit from the detection of
thyroid autoantibodies by means of
these highly sensitive assays are
pregnant women. During pregnancy
the presence of thyroid antibodies has
been correlated with an increased rate
of miscarriage.
Following delivery, postpartum
thyroiditis is a fairly common event
which causes symptoms in women
because of hypothyroidism. Studies
have demonstrated that the prevalence
of post pactum thyroid disease (PPTD)
is about 8-10% in the US population in
the 4-8 month post delivery period.
Furthermore, almost all such patients
have anti TPO antibodies detectable
early in pregnancy and with a post
partum rise. More than 33% of such
Page 17

anti TPO positive patients develop
some form of PPI'D, in particular
those patients with the highest levels of
thyroid antibodies.

Although somewhat redundant, the
ordering of both tests is suggested as
TPO is more sensitive but less specific
than TgAb.

The indications for ordering these two
tests anti-TPO autoantibodies and antithyroglobulin antibodies (TgAb) are
summarized as follows:

Alternatively, Autoimmune thyroid
disease is also associated with
stimulating antibodies such as thyroid
stimulating Immunoglobulin (TSI).
Studies have shown that TSI is present
in 80-90% of patients with active
Grave's disease and absent in patients
with remission. Measuring TSI is
helpful in monitoring Grave's disease
during pregnancy, in post pregnancy
management and in neonatal Grave's
disease.

1)

TSH elevation of unknown
etiology.

2)

Goiter of unknown etiology.

3)

Screening for risk of postpartum
thyroiditis (during pregnancy
and after delivery.

4)

Familial evaluation for establish
cause of genetic thyroid disease.

5)

6)

Risk assessment for the
development of thyroid
dysfunction during drug
treatment (lithium, interferon,
cytokines).

Gerald E. Clement, Ph.D.
Technical Director
Clinical Laboratories

Larry N. Merkle, M.D.
Chief, Endocrinology

Evaluation of suspected
polyglandular autoimmune
diseases such as pernicious
anemia, Addison's disease,
vitiligo, Type I diabetes
mellitus, and certain hepatic
disorders as chronic active
hepatitis and hepatitis C.
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NATIONAL BLOOD RESOURCE EDUCATION PROGRAM'S

NATIONAL INSTITUTES OF HEALTH
National Heart, Lung, and Blood Institute

TRANSFUSION ALERT

Indications for the Use of Red Blood Cells,
Platelets, and. Fresh Frozen Plasma
Rationale for
Component Use

Red Blood Cell
Transfusion
Red blood cell (RB() transfusions increase oxygen-carrying
capacity in anemic patients. Transfusing 1 unit of RBC's will usually
increase the hemoglobin by about
1 g/dL and the hematocrit by 2-3
percentage points in the average 70
kg adult.
In deciding whether to transfuse
a specific patient. the physician
should consider the age of the
person; the etiology, degree, and

Platelet Transfusion
Platelet transfusions are administered to control or prevent bleeding
associated with deficiencies in
platelet number or function. One
unit of platelet concentrate should
increase the platelet count in the
average adult recipient by at least
5,000 platelets/f.lL
Prophylactic platelet transfusion
may be indicated to pre-·em bleeding in patients with severe thrombocytopenia. For the clinically stable
patient with an intact vascular
system and normal platelet function.
prophylactic platelet transfusions

Blnod transfusion can be lifesaving therapy for patients with a
variety of medical and surgical conditions. Advances in the use of blood •
components have made whole blood tratzsfusions rarely necessary. Blcod
component therapy provides better treatment for the patient by giving
only the specific component needed. Such therapy helps .to conserve
blood resources because compommtsfrom I unit of blood can be used to
treat several patients.

Transfuse
Red Blood Cells:

Do Not Transfuse
Red Blood Cells:

+ Only to increase oxygen-

• For volume expansion only
• In place of a hematinic .
• To enhance wound healing
• To improve general ~ell
being."

carrying capacity in anemic
patients.

time course of the anemia: hemodynamic stability; and the presence of
coexisting cardiac. pulmonary. or
vascular conditions. There is no
across-the-board threshold or
·'trigger.., Both undertransfusion and
ovemansfusion should be avoided.
~'hen a treatable cause of
anemia can ue identified and time

Transfuse Platelets:

+ To control or prevent
bleeding associated with
deficiencies in platelet
number or function.

may be indicated for platelet counts
of <10.000-20,000/f.lL. A patient
undergoing an operation or other
invasive procedure is unlikely to
benefit from prophylactic platelet
transfusions if the platelet count
is 50.000/f.lL or more and
thrombocytopenia is the sole
abnormality. Platelet transfusions at
higher platelet counts may be
required for patients with systemic

permits. specific therapy (e.g .. ,.itamin
B... iron. folate) should be used in
preference to transfusion. If volume
expanders are indicated. fluids such
as crystalloid or nonblood colloid .
solutions should be administered.

Do Not Transfuse
Platelets:
• To patients with immune or
thrombotic thrombocytopenic purpura (ITP or
TIP), unless there is clutically significant bleeding
+ Prophylactically with
massive blood transfusion
• Prophylactically following
cardiopulmonary bypass.

bleeding and for patients at higher
risk of bleeding because of additional coagulation defects. sepsis. or
platelet dysfunction related to
medication or disease.
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Fresh Frozen Plasma
Transfusion
Fresh frozen plasma ( FFP)
transfusions should be administered
only to increase the level of clotting
f:.~ctors in patients with :1 demonstrated deficiency. Labor.ltory tests
should be used to monitor the
patient with a suspected dotting
disorder. If prothrombin time (PT)
and partial thromboplastin time
<PTT) are <1. 5 times nom1al, FFP
transfusion is rarely indicated.
Patients who have been given
the anticoagulant warfarin sodium

+To increase the level of
·dotting factors in patients
with a demonstrated
deficiency.

l. Office of ;\oledical Applications of Research.
~ational

Institutes of Health. -Fresh f"::JZen
Plasma: Indications and Risks ... journal of
th<• American Jtedical Association 253<-i):
551-553. jan 25. 1985.

l. Ollke of Medic:1l Applications of Research.

:-.:ational Institutes of Health. -Platelet
TrJnsfusion Therapy." journal of the
American Medical Association 257(13):
1777-1780. Apr 3. 1987.

administering vitamin K.
Patients with thrombotic
thrombocytopenic purpura (TfP)
or hemolytic uremic syndrome
<HCS) may benefit from FFP
transfusion.

• Fatal bemo(rtic trcmsjitsicm
rew.:tio11s c:m occur c ;.~pproxi
matdy 1:600.000>. They are
caused by an -~BO incompatibility
primarily due to errors in patient
id<=ntification at the bedside.

• Recipients of ;.~ny blood component may produce ;.~ntibodies
;1gainst donor antigens. i.e ..
alloim mzm i=ation. This condition c:m result in an inadequate
response to trJ.nsfusion.

Other infectious diseases or
agents may be transmitted via
transfusion <e.g .. hepatitis B
[1:200.000]. HTLV-L II [1:50.0001.
cytomegalovirus. and those
causing malaria and orher rare
diseases [less than 1:1 million]).

• Allergic reactiolls. jebnil! reactions. and circulatory Ol'erioad
may abo occur.

seronegati\'e hlood donations. In: Program
Abstre~cts of the Fijih .\"ational Fun11n on
AIDS. Hepatitis. mrd Other Blood-Bonre
Diseases: 1992 ~lar 29-Apr 1: Atlanta.
Princeton. Nj: Symedco: 1992. p. 37.

3. Office of !\lledical Applications of Research.
National Institutes of He:...th. "Perioper:nive
Red Cell TrJnsfusion." jounwl ufthe
American Jofedical.'!ssociation 260< 18):
2700-T03. Nov 11. 1988.
-i.

Donahue JG. :\lunoz A. :"\ess P. et al. The
dedining risk of post-trJnsfusion hepatitis
C vin1s infection. New England journal of
Jtedicim! 327C 6):369·373. 1992.

6. Dodd RY. The risk of transfusion-trJnsmitted infection . .\ezt· E11gland jozmwl of
J1edicine327(6l:-!l9--i21. 1992.

-. LindenJ. Paul B. Dressler KP. A report of
104 trJnsfusion errors in ~e"'· York state.
Trcmsjizsion 32C">:601-606. 1992.

5. Petersen LR. Satten G. Dodd RY. et al.
Current estimates of the infectious window
period Jnu risk of HIV infection from

National Blood Resource Education Program Expert Panel on the Indications
for the Use of Red Blood Cells, Platelets, and Fresh Frozen Plasma
Linda C. Stehling, .H.D., Cbair

Delos M. Cosgrove. .H.D.
GeraldS. Moss, M.D.
Cbarles A. Schiffer, J!.D.
Sherrill}. Slichter. .H.D.
Edzmrd L. Sn_vder. .H.D.

NHLBI Panel Members
Harvey G. Klein, .H.D.
Paul R. JlcCurdy, M.D.
Elaine .H. Sloand. .H.D.
NBREP Coordinator
Susan D. Rogus. R..Y.. Jf.S.

Prophylactically with
massive blood transfusion
cardiopulmonary bypass.

• Human illlmullodejlciency
l'imsr esJ presently poses a
relativelv small hazard. The wide
range of estimated risk ( 1:-iO.OOO
to 1:225.000 l ret1ects geographic
variance.
•

As a nutritional supplement

+ Prophylactically following

positin~ units. the estimated risk
of transfusion-related hepatitis C
has heen decreased to approximately 1:3.300.

• Hepatitis C cints can be transmitted by blood transfusion. With the
introduction of a screening test to
detect anti-HCV in donated
blood, and the discarding of

References

+
+

become deficient in vitamin
K-dependent coagulation factors II.
VII. IX. and.X. If these patients are
bleeding or require emergency
surgery. they may be candidates for
FFP tr:msfusion to achieve immediate hemostasis when time does not
permit ~varfarin reversal by stopping
the drug and. ~vhen necessary.

Risks Common to All
Blood Components
Infection and alloimmunization
are the major complications associated •vith transfusion of blood
components. There is a relationship
berween these risks and the number
of donor exposures. The risk of
infection is geographically variable.
Risks listed below are per unit
transfused.

Do Not Transfuse
Fresh Frozen Plasma:
+ For volume expansion

Transfuse Fresh Frozen
Plasma:

••

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
0
ublic Health Service
National Institutes of Health
National Blood Resource Education Program

'~ Office of Prevention, Education. and Control

W National Heart. Lung, and Blood Institute
NIH Publication No. 93-2974
Revised August 1993
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P & T HIGHLIGHTS
The following action were taken at the November 12, 1994 Pharmacy and
Therapeutics Committee Meeting- Maria Barr, Pharm.D., Barbara Leri, Pharm.D.,
Richard Townsend, R.Ph.

FORMULARY ADDITIONS
Venlafaxine (Effexor, Wyeth-Ayerst) was
approved for addition to the formulary.
Venlafaxine is a bicyclic antidepressant that
inhibits reuptake of serotonin,
norepinephrine, and to a lesser extent,
dopamine.
Unlike the tricyclic
antidepressants, the drug does not possess
anticholinergic activity.
Venlafaxine
appears to have a more rapid onset of action
than the antidepressants currently available.
However, direct comparisons with · other
agents are lacking and the data is limited.

venlafaxine.
Regular blood pressure
monitoring is recommended for all patients.
Dosage reduction or discontinuation of
therapy should be considered in patients
with a sustained increase in blood pressure.
Venlafaxine should not be used in
combination with monoamine oxidase
inhibitors (MAOI) or within 14 days of
discontinuing MAOI therapy.

STOP ..... THE BLEEDING!
Aprotinin (TrasylolR) was added to the

The recommended dose of Venlafaxine is
75mg/day initially, in i or 3 divided doses.
Titration in increments of75mg/day at 4 day
intervals to a total of 225mg/day is
recommended.
Patients with severe
depression may require up to 375mg/day in
3 divided doses.
The dose should be
reduced 50% in patients with hepatic
impairment. Dosage adjustments may be
required in patients with renal impairment.
For patients in hemodialysis, the dose
should be decreased 50% and administered
post-dialysis.
Adverse reactions are similar to other
selective serotonin reuptake inhibitors.
Nausea. headache, anxiety. anorexia,
vomiting, somnolence. sweating, dizziness,
blurred vision, and sexual dysfunction are
the most common during treatment with

formulary in May, 1994 for a 3 month
evaluation. Aprotinin, a bovine derived
protein, is approved for use in
cardiothoracic patients who are at high risk
of bleeding during their procedure.
Approval of Aprotinin occurred following
development of specific criteria for use by
the cardiothoracic division. An evaluation
was conducted reviewing all patients who
received Aprotinin through 8/94.
Additionally, a historical control group was
selected for comparison to the Aprotinin
patients. A total of 39 Aprotinin patients
were compared to 18 controls. The controls
were selected by the perfusion department
based on type of procedure and surgeon.
The results of the preliminary evaluation are
listed in Table 1 on the next page:
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Table I· APROTININ- PRELIMINARY EVALUATION RESULTS
Control

(18)

..$_ 2 units
· PRBC (10)

> 2 units
PRBC (8)

Study

(38)*

2 units
PRBC (19)

..$..

> 2 units
PRBC but..$..
8 units
PRBC (13)

Ave LOS

16

15.2

17.3

14

13.8

15.7

Ave OHU LOS

4

2.7

4.5

5

2.8

7.4

Ave hrs until CT d/c'd

46

46.4

45.8

45

43.6

44.2

Ave total CT drainage
post-op (ml)

1046

840

1303

1222

635

978

Total blood loss (ml)

1228

790

1700

1054

810

988

Ave CPB (min)

168

119

213

185

166

170

Ave time of procedure
(min)

326

292

368

399

353

385

Ave PRBC (units)

4

5

Ave units

11

10

Ave cost of Aprotinin
($)

N/A

N/A

NIA

1504

1524

1494

Ave cost of blood
products ($)

834

82

1725

959

232

1061

:l pat1ents rece1ved >
A total of 5 patients expired who received Aprotinin during this evaluation period.

* 1 patient was not able to be assessed; expired prior to surgery.

No conclusions can be drawn based on the
preliminary data due to the small sample
size of both groups as well as problems
identified in matching the two groups.
Trends towards shorter total lengths of stay,
a decrease in total blood loss and possible or
decrease in total blood products used seems
to be evident on initial evaluation. The data
is being forwarded to the CT division for
review and comment. Further evaluation
may be warranted encompassing the CT
division's input and utilizing a more
accurate method of matching control
patients.

THE
LINES
OF
COMMUNICATION ARE OPEN!
Aprotinin (TrasylolR). a medication
approved for use in high-risk cardiothoracic
surgery. is a bovine protein which may
cause an antigen-antibody reaction.
Anaphylaxis may result with repeat exposure
and possibly even with initial exposure.

~

umts PRHC.

Due to the risk of anaphylaxis, an extensive
campaign has been instituted to prevent any
serious adverse events specifically related to
the allergic potential of this medication.
Aprotinin is being addressed specifically for
a variety of reasons. First, many health
care professionals may be unaware of
Aprotinin administration since it is utilized
principally in .the operating room.
Secondly, the patient may not be aware they
received Aprotinin during surgery. Finally,
though only approved for CT surgery
presently, the potential for use of Aprotinin
in other high risk procedures exists. This
may place the patient at risk without proper
education and communication of Aprotinin
use.
Several mechanisms of documentation have
been initiated. The surgeon will document
Aprotinin's use in both post-operative note
as well as in the operative summary. The
attending physician will be documenting
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Aprotinin in the discharge summary. This
will assure other institutions who care for
the patient and receive a copy of the
discharge summary will be made aware of
Aprotinin administration. Anesthesia will be
placing bright colored stickers on the front
of the chart and in the progress notes to
assure other staff members are informed of
Aprotinin administration. (The stickers are
not yet available). Once an order for
Aprotinin is received, the pharmacy
department will enter Aprotinin in the
allergy section of PHAMIS. This will
assure that if Aprotinin is ordered a second
time or on a subsequent admission, the
pharmacist will be alerted to inform the
physician of previous exposure.
As a
method of insuring the patient is educated,
a patient education sheet will be reviewed
with the patient by the discharge nurse or
physician. Following discharge, the patient
will receive a wallet card stating Aprotinin
was given to them during CT surgery with
a cover letter to explain its purpose.
Allergy identification information will also
be provided to the pjlient.

MED ERROR PREVENTION
A medication error quality review form
(MEQRF) is a multidisciplinary document
developed to gather information on
medication errors and to identify areas for
future prevention. The pilot period has been
completed and the form is ready for
housewide use. The MEQRF is intended to
be used by all disciplines.

UNIT BASED PHARMACIST PATIENT FOCUSED CARE
The seventh floor has had a pilot project
over the past few months of having a
pharmacist on the units to perform order
entry, drug information consults, patient
interviews and consults, ·and nursing
inservices to name a few.
Positive
outcomes of the project included a decrease
in turn around time, increased nursing
satisfaction and acceptance of pharmacy
intervention/ recommendations by the
attending physicians. Results of the project
was presented to JCAHO during the
Performance Improvement Session. Keep
up the good work!

ALCOHOL - METRONIDAZOLE
INTERACTION
Disulfiram reactions (characterized as
flushing, nausea, and vomiting) may occur
when metronidazole is given concurrently
with alcohol or alcohol-containing
medications. This is a dose-related reaction
with the incidence reported to be anywhere
from 2% to 24%.
Many oral elixirs and solutions contain a
certain percentage of alcohol. Many health
care providers may not be aware of
parenteral products• that also contain alcohol.
(See Table 2 on the next page).
Alcohol-free and acceptable alternative
agents can be provided for those patients on
metronidazole experiencing a disulfiram like
reaction.

)
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Table 2: ALCOHOL CONTENT OF PARENTERAL FORMULARY MEDICATIONS

I

PARENTERAL PRODUCT

I

ETOH CONTENT

IV TMP-Sulfa (BactrirnR)

10%

IV Nitroglycerin, Abbott

8.4%

IV Phenytoin (DilantinR)

10%

IV Diazepam (ValiumR)

10%

IV Pentobarbital .

10%

IV Ketorolac (ToradolR)

10%

I

32.9%

IV Cyclosporin

CO$T CORRECTIONS ON THE
REVISED ANTIBIOGRAM

PEDIATRIC ANTIBIOTIC ORDER
FORM

It has been brought to the pharmacy's
attention that a few daily antibiotic
acquisition costs listed on the revised
antibiogram had omission errors.
We
apologize for this error and would like to
provide the corrections at this time. The
following antibiotic costs should have been
reported with ranges as follows:

The committee approved a form for use in
prescribing antibiotics for pediatric patients.

Ampicillin!Sulbactam
Ceftazidirne
Cefuroxirne

$20.00-$40.00
$33.30-$66.60
$15.90-$31.65

Please note that the Parenteral Antibiotic
Order Sheet contains the correct daily
acquisition costs for parenteral formulary
antimicrobial agents.

The form
includes an area for
documentation of the patient's weight and
pediatric dosage guidelines for formulary
drugs. Guidelines for commonly prescribed
antibiotics are on the back of the page.
Development of the form was a
multidisciplinary effort involving the
departments of Pharmacy, Pediatrics, and
Infectious Disease. The form will be made
available on all ' units where care for
pediatric patients is provided. Indication
and dosing guidelines are attached.
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Parenteral Antibiotic Guidelines for Pediatric Patients**
DRUG

AGE

Acyclovir
(Zovira.x)
Ampicillin
(Omnipen)

0-7 days
>7 days

Cefazolin
(Ancel)

0-7 days
>7 days

Cefotaxime
(Ciaforan)

0-7 days
8-30 days
>30 days

Ceftria.xone
(Rocephin)

· INDICATION

(Maximum Dose)

Cutaneous HSV
HSV Encephalitis. Varicella

S mglkg IV q8h, infuse over I hour
I 0 mg/kg IV q8h, infuse over I hour
(45 mg/kg/day)

Meningitis
Other
Meningitis
Other

SO
SO
SO
2S

mg/kg
mg/kg
mglkg
mglkg

IV
IV
IV
IV

q8h
or IM ql2h
q6h
or IM q6h
(400 mglkglday or 12 grams)

20 mglkg IV or IM q 12h
25 mglkg IV or IM q8h
(100 mglkglday or 6 grams)
Meningitis
Meningitis
Meningitis

SO mglkg IV or IM
SO mglkg IV or IM
50 mg/kg IV or IM
(300

Meningitis
Other

100 mglkg IV or IM q24h
SO mglkg IV or IM q24h
(100 mglkglday or 4 grams)

ql2h
q8h
q6h
mglkg/day or 12 grams)

25-50 mg/kg IV or IM q8h
(300 mg/kg/day or 9 grams)

Cefuroxime
(Zinacef)

)

DOSAGE

Clindamycin
(Cieocin)

0-7 days
8-30 days
>30 days

~ mg/kg IV or IM q8h
7 mglkg IV or IM q8h
10 mg/kg IV or IM q8h
(40 mglkg/day)

Erythromycin
(Erythrocin)

0-7 days
8-30 days
>30 days

10 mglkg IV ql2h
I 0 mglkg IV q8h
I 0 mglkg IV q6h
(. 50 mglkg/day or 4 2rams)

Gentamicin
(Garamycin)

0-7 days
>7 days

Nafcillin
(Unipen)

0-7 days
>7 days

Penicillin G
(Pfizerpen)

0-7 days
>7 days
>I year

Vancomycin
(Vancocin)

"*

0-7 days
8-30 days
>30 days

2.5 mglkg IV or IM ql2h
2.5 mg/kg IV or IM q8h
(Based on serum levels)
Meningitis
Other
Meningitis
Other

Meningitis
Other
Meningitis
Other
ivlen ingitis
Other

Meningitis
Other

50
25
50
25

mglkg
mglkg
mg/kg
mglkg

IV
IV
IV
IV

or IM
or IM
or IM
or IM
(200

q8h
q8h
q6h
q6h
mg/kg/day or 12 grams)

50,000 units/kg IV q8h
units/kg IV q8h
50.006 units/kg IV q6h
25,000 units/kg IV q6h
66,500 units/kg IV q4h
50.000 units/kg IV q6h
(500.000 units/kg/day or 24 million units/d:ly)
2~.000

15
15
15
I0

mglkg
mgJkg
mg.•kg
mg.•kg

I\' ql2h
I\· q8h
I\' q6h
1\' q6h
(60 mg/k~/day)

General dosage guidelines for pediatric patients are listed. Drug therap~· should be tailored to meet the needs of
the patient. In special circumstances such as premature infants or patients with renal or hepatic impairment. consult
the appropriate literature or call Clinical Pharmacy Services (17-#2797, CC-888-t) for additional information.

)
Page 25

..

FYI- ORAL FLUCONAZOLE'S
NEW INDICATION
Fluconazole (DiflucanR) recently received
FDA approval for a new indication. Single
dose therapy with 150mg oral fluconazole is
indicated for the treatment of vaginal
candidiasis. It has been found to be equally
AGENT

efficacious as 7 day therapy with
intravaginal clotrimazole or miconazole. A
cost comparison of the OTC and Rx
available agents are listed below.

DOSE AND DURATION

$ PER THERAPY

Butoconazole Vaginal Cream 2%

1· applicant intravaginally
QHS x 3 days

$18.35 OTC

Clotrimazole Vaginal Cream 1%

1 applicant intravaginally
QHS x 7 days

$12.00 OTC

Clotrimazole Vaginal Tablet

1OOmg tablet intravaginally
QHS x 7 days

$12.85 OTC

Clotrirnazole Vaginal Tablet

500mg tablet intravaginally x

$12.71 Rx

one~

Miconazole Vaginal Cream 2%

1 applicant intravaginally
QHS x 7 days

$12.85 OTC

Miconazole Vaginal Suppository

1OOmg suppository
intravaginally QHS x 7 days

$12.85 OTC

Miconazole Vaginal Suppository

200mg suppository
intravaginally QHS x 3 days

$23.22 Rx

Nystatin Vaginal Tablet

1 tablet intravaginally QHS x
14 days

$6.44

Terconazole Vaginal Cream 0.4%

1 applicant intravaginally
QHS x 7 days

$22.26 Rx

Terconazole Vaginal Suppository

80mg vaginal suppository
QHS x 3 days

Fluconazole

150mg single oral dose

Single dose oral therapy with fluconazole
offers a more convenient method for treating
vaginal candidiasis. Commonly reported
adverse e~··.:cts include nausea. vomiting.
diarrhea ... ~·,Jominal pain and headache.

;

I

Rx

$22.26 Rx
$10.62 Rx

Anaphylactiod reactions have been reported
with single doses. The impact of single
dose fluconazole use on Candida resistanct:
patterns is not know at this time.

pl.lll~94.hi
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CRITERiA FOR RECOMMENDATION FOR APPOINTMENT TO THE

PENNSYLVAN1A STATE UNIVERSITY FACULTY
1.

Attending and Professional staff of the Lehigh Valley Hospital (LVH) may be considered
for appointment to the Pennsylvania State University (PSU) faculty.

2.

Appointment to the PSU faculty will be the only university faculty appoiQ.tment held by
the faculty member, except for adjunct or honorary appointments at other universities.

3.

Appointment Process:

4.

5.

a.

The appointment of Clinical Assistant Professor will be made by PSU
upon recommendation of L VH. This will be the standard appointment for
LVH attending physicians.

b.

Advanced level appointments will require review of the application by the
L VH Faculty Appointments Committee and the PSU Faculty Affairs
Committee.

Pennsylvania State University has three categories for academic rank:
a.

Clinical [PrefiXed]: Title indicates primary involvement in patient care
with teaching as a secondary commitment. The majority of affiliate
hospital (LVH) appointments will be in this category.

b.

Clinical-Educator[SufrJXed Clinical]: Title indicates evidence of
scholarly productivity in addition to patient care and teaching. Some L VH
appointments will be in this category.

c.

Scientist-Educator [Unmodified]: Title indicates involvement in scholarly
patient care related activities including clinical or basic research and
appropriate scholarly publications. Only a few LVH appointments will be
in this category. Demonstrated academic leadership is required.

General Criteria for all Academic Appointments:
Note: Not every faculty member should be expected to demonstrate excellence in
each criterion. However, for all appointments, teaching ability and effectiveness
at L VH will be a prime consideration.
a.

Teaching ability and effectiveness;
1.

Commitment to student teaching;

ii.

Commitment to resident teaching;
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b.

c.

d.

e.

iii.

Adequate student/resident evaluations of teaching;

1v.

Recommendations from
effectiveness;

v.

Awards, prizes or certificates
effectiveness, skills or innovation;

previous employment of teaching
acknowledging

teaching

Research and/or creative accomplishments;

i.

Publication in peer reviewed journals;

11.

Non-research publications such as book chapters, books (including
editorship), computerized instruction and teaching materials related
to field or specialty;

m.

Grants or awards for basic, clinical, applied or outcomes-based
research;

Scholarship and mastery of subject matter;
i.

Appropriate discipline Board diplomate;

u.

Journal reviewer or editor;

111.

Participation in regional or national organizations, including study
sections;

iv.

Invitation to speak at other institutions;

Patient Care (where applicable);
1.

Member of active medical staff, without restriction;

n.

Recognition by peers of superior clinical skills;

Service to the Hospital and the public in the profession;
i.

Participation in CME education as faculty;

n.

Service on hospital committees of appointed positions;

iii.

Service in the administrative aspects of the teaching program for
students or residents.
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6.

Criteria for Advanced Prefixed Academic Appointment:
a.

b.

Clinical Associate Professor
i.

Publication in journals, books, monographs or symposia and
presentation at regional or national meetings;

ii.

Clinical excellence acknowledgement by peers [letters of
recommendation];

111.

Regional reputation [society memberships, site reviewer or
inspector for national accrediting agency, letters of
recommendation];

IV.

Education demonstrated commitment to teaching, curriculum
planning or course leadership;

v.

Service commitment as evidenced by committee membership and
chairmanship, division and/or section leadership.

v1.

Minimum of three years at the Assistant Professor rank, or
appropriate service at another institution or university.

Clinical Professor
1.

Publication in peer reviewed journals, books, monographs or
symposia, editorship, presentation at regional and national
meetings;

ii.

Regional or national leadership in clinical medicine through
acknowledgement by peers of clinical excellence [letters of
recommendation];

iii.

Membership in national societies, academic recognitions or
awards;

IV.

Lead~rship

v.

Commitment to hospital service functions as evidenced by
committee membership and chairmanship, division and/or section
chief;

in educational activities at LVH is required;
educational endeavors at the regional or national level will also be
considered;
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v1.

7.

Criteria for Advanced Clinical-Educator or Scientist-Educator:
a.

b.

8.

Minimum of three years at the Associate Professor rank, or
appropriate service at another institution or university.

Clinical-Educator
1.

Regular publication in peer-reviewed journals;

u.

Acknowledgement by peers of clinical excellence [letters of
recommendation];

iii.

Regional reputation [society membership, presentation at
regional or national meetings, site reviewer or inspector for
research grant or national accrediting agency, letters of
recommendation];

iv.

Demonstrated innovative approaches to teaching and
training, curriculum planning or course leadership;

v.

Minimum of four years at the next lower rank, or
appropriate service at another institution or university.

Scientist-Educator
1.

Regular publication in peer reviewed journals
demonstrating continued, focused interest in one or more
areas of scientific or medical interest;

ii.

Evidence of recognized leadership locally, regionally, and
nationally in the chosen specialty or subspecialty;

iii.

Invitations to membership or fellowship in national
societies, academic recognitions or awards, hospital and/or
department leadership;

iv.

Testimony of nationally recognized practitioners in the
same field;

v.

Minimum of four years at the next lower rank, or
appropriate serv;<·:; at another institution or university.

Duration of Appointment:
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9.

a.

Prefixed Clinical appointments will be for three years;

b.

Clinical-Educator and Scientist-Educator will be for four years;

c.

LVH will notify PSU should the individual terminate his/her
affiliation with LVH. PSU shall have the right to review and
withdraw the appointment upon this notification.

PSU guidelines will be used for definition and appointment for ranks of lecturer,
instructor, and librarian.

psuappt.fnl
10/16/94

)
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LEHI§VAJI,EY

Physician Well-Being
Group Meeting Schedule

1995

HOSPITAL

Listed below are the dates for the P,hysician Well-Being Group meetings for 1995. All
meetings will be held in the Cafeteria Conference Room at Lehigh Valley Hospital,
Cedar Crest & 1-78, from 6 to 7:30 p.m., unless otherwise noted.

)

Mondays

Wednesdays

January 23

January 11 - Classroom 3

February 20

February 8 - Classroom 3

March 20

March 8 - Classroom 4

April 17

April 5

May 15

May 3 - Classroom. 2

June 12

May 31

July 10

June 28

August 7

July 26

October 2

August 23

October 30

September 20

November 27

October 18 - Classroom 2
November 15 - Classroom 2
December 13

)
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Non-Profit Org.
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Allentown, PA
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